knowledge -WSS

knowledge

author：comprehensive 2025-09-28 13:23:51 - browse：29499

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Inside the rise of 'mukbang' eating videos

leisure time

focus

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Pentagon will tighten controls on classified information after Discord leak

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Eli Lilly’s Mounjaro succeeds in second weight

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

How to save PrEP access — and even expand it

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

After affirmative action ruling, medical educators look to 'holistic review'

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

Medical records are filled with copy

How to fix the rural physician shortage in the U.S.

The cancer drug shortage isn’t new — and neither are the solutions

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

State Dept. review finds Biden bears some blame for Afghanistan failures

2 million sign

leisure time

Novo pauses ads for weight loss drug Wegovy amid demand

Biden administration plans revamp of organ transplant system

Altering the blood type of lungs raises potential for universal organs for transplants

China dismisses criticism of top diplomat's comments appearing to push for race

Israel withdraws forces after 2

Pentagon will tighten controls on classified information after Discord leak

focus

leisure time

focus

knowledge